Finerenone Significantly Reduces Cardiovascular Death, Heart Failure in the FINEARTS-HF Trial
Pharmacy Times
AUGUST 10, 2024
Non-steroidal mineralocorticoid receptor antagonist, finerenone, demonstrated improved efficacy compared with existing steroidal treatment for patients.
Let's personalize your content